Clinical profile, Management and Outcomes in a Cohort of Elderly and Highly Comorbid Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban in Routine Practice

References

• Coleman C , WeedaE, NguyenEet al. Effectiveness and safety of Rivaroxaban vs Wafarin in patients 80+ years of age with non-valvular atrial fibrillation . Eur. Heart J. Qual. Care Clin. Outcomes doi:10.1093/ehjqcco/qcx044 ( 2017 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar
• Suárez Fernández C , FormigaF, CamafortMet al. Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach . BMC Cardiovasc. Disord.15, 143 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Wang Y , SinghS, BajorekB . Old age, high risk medication, polypharmacy: a ‘trilogy’ of risks in older patients with atrial fibrillation . Pharm. Pract. (Granada)14 ( 2 ), 706 ( 2016 ).
   PubMedGoogle Scholar
• Suárez Fernández C , MostazaJM, Castilla GuerraLet al. Adherence to recommendations of the Therapeutic Positioning Report about treatment with oral anticoagulants in elderly patients with atrial fibrillation. The ESPARTA study . Med. Clin. (Barc.) doi:10.1016/j.medcli.2017.07.025 ( 2017 ) ( Epub ahead of print ).
   Web of Science ®Google Scholar
• Patti G , LucernaM, PecenLet al. Thromboembolic risk, bleeding outcomes and effect of different antithrombotic strategies in very elderly patients with atrial fibrillation: a sub-analysis from the PREFER in AF (PREvention oF Thromboembolic Events-European Registry in Atrial Fibrillation) . J. Am. Heart Assoc.6 ( 7 ), doi:10.1161/JAHA.117.005657 ( 2017 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar
• Karamichalakis N , LetsasKP, VlachosKet al. Managing atrial fibrillation in the very elderly patient: challenges and solutions . Vasc. Health Risk Manag.11, 555 – 562 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Nguyen TN , CummingRG, HilmerSN . The Impact of frailty on mortality, length of stay and re-hospitalisation in older patients with atrial fibrillation . Heart Lung Circ.25 ( 6 ), 551 – 557 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Ruff CT , GiuglianoRP, BraunwaldEet al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials . Lancet383 ( 9921 ), 955 – 962 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Oertel LB , FogertyAE . Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation . J. Am. Assoc. Nurse Pract.29 ( 9 ), 551 – 561 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Bando S , NishikadoA, HiuraNet al. Efficacy and safety of rivaroxaban in extreme elderly patients with atrial fibrillation: Analysis of the Shikoku Rivaroxaban Registry Trial (SRRT) . J. Cardiol.71 ( 2 ), 197 – 201 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Patel MR , MahaffeyKW, GargJet al. ROCKET AF Investigators . Rivaroxaban versus warfarin in nonvalvular atrial fibrillation . N. Engl. J. Med.365 ( 10 ), 883 – 891 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Halperin JL , HankeyGJ, WojdylaDMet al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) . Circulation130 ( 2 ), 138 – 146 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Kirchhof P , BenussiS, KotechaDet al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS . Eur. Heart J.37 ( 38 ), 2893 – 2962 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Lip GY , NieuwlaatR, PistersR, LaneDA, CrijnsHJ . Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation . Chest137 ( 2 ), 263 – 272 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Pisters R , laneDA, NieuwlaatR, de VosCB, CrijnsHJ, LipGY . A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey . Chest138 ( 5 ), 1093 – 1100 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA) . Xarelto®, “Summary of Product Characteristics” . www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf
   Google Scholar
• Chowdhry U , JacquesA, KarovitchA, GiguèreP, NguyenML . Appropriateness of dabigatran and rivaroxaban prescribing for hospital inpatients . Can. J. Hosp. Pharm.69 ( 3 ), 194 – 201 ( 2016 ).
   PubMedGoogle Scholar
• Elewa H , El-MakatyH, AliZ . Appropriateness of dabigatran and rivaroxaban prescribing in Qatar: a 5-year experience . J. Cardiovasc. Pharmacol. Ther.23 ( 2 ), 155 – 161 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Whitworth MM , HaaseKK, FikeDS, BharadwajRM, YoungRB, MacLaughlinEJ . Utilization and prescribing patterns of direct oral anticoagulants . Int. J. Gen. Med.10, 87 – 94 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Nielsen PB , Skj⊘thF, S⊘gaardM, KjældgaardJN, LipGY, LarsenTB . Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study . BMJ356, j510 ( 2017 ).
   PubMedGoogle Scholar
• Yao X , ShahND, SangaralinghamLR, GershBJ, NoseworthyPA . Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction . J. Am. Coll. Cardiol.69 ( 23 ), 2779 – 2790 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Diener HC , AisenbergJ, AnsellJet al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1 . Eur. Heart J.38 ( 12 ), 852 – 859 ( 2017 ).
   PubMedGoogle Scholar
• Lobos-Bejarano JM , BarriosV, Polo-GarcíaJet al. Evaluation of SAMe-TT2R2 score and other clinical factors influencing the quality of anticoagulation therapy in non-valvular atrial fibrillation: a nationwide study in Spain . Curr. Med. Res. Opin.32 ( 7 ), 1201 – 1207 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Barrios V , EscobarC, PrietoLet al. Anticoagulation control in patients with nonvalvular atrial fibrillation attended at primary care centers in Spain: the PAULA study . Rev. Esp. Cardiol. (Engl. Ed.)68 ( 9 ), 769 – 776 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Anguita M , BertomeuV, CequierÁ . Quality of vitamin K antagonist anticoagulation in Spain: prevalence of poor control and associated factors . Rev. Esp. Cardiol. (Engl. Ed.)68 ( 9 ), 761 – 768 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Contreras Muruaga MDM , VivancosJ, ReigGet al. Satisfaction, quality of life and perception of patients regarding burdens and benefits of vitamin K antagonists compared with direct oral anticoagulants in patients with nonvalvular atrial fibrillation . J. Comp. Eff. Res.6 ( 4 ), 303 – 312 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Camm AJ , FoxKAA, PetersonE . Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention . Europace20 ( 1 ), 1 – 11 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Hecker J , MartenS, KellerLet al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry . Thromb. Haemost.115 ( 5 ), 939 – 949 ( 2016 ).
   PubMed Web of Science ®Google Scholar